Fetale und neonatale Alloimmunthrombozytopenie: Pathophysiologie, Diagnostik, Therapie

U. J. Sachs; T. Bakchoul; G. Bein

doi:10.1055/s-0031-1283993

Transfusionsmedizin, Inhaltsverzeichnis

Transfusionsmedizin 2012; 2(2): 77-89
DOI: 10.1055/s-0031-1283993

Übersicht

Fetale und neonatale Alloimmunthrombozytopenie: Pathophysiologie, Diagnostik, Therapie

Fetal / Neonatal Alloimmune Thrombocytopenia: Pathophysiology, Diagnosis and Therapy

U. J. Sachs

¹Institut für Klinische Immunologie, Justus-Liebig-Universität Gießen, Universitätsklinikum Gießen und Marburg GmbH

,

T. Bakchoul

²Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt-Universität Greifswald

,

G. Bein

¹Institut für Klinische Immunologie, Justus-Liebig-Universität Gießen, Universitätsklinikum Gießen und Marburg GmbH

› Institutsangaben

Abstract

Zusammenfassung

Bei der fetalen und neonatalen Alloimmunthrombozytopenie (FNAIT) immunisiert sich die Schwangere gegen väterliche Merkmale auf den fetalen Thrombozyten. Der diaplazentare Übergang dieser Antikörper in den Fetalkreislauf führt zur Thrombozytopenie des Feten oder Neugeborenen. Eine gefürchtete Komplikation der FNAIT ist die intrakranielle Blutung. Für immunisierte Frauen mit erneutem Kinderwunsch ergeben sich besondere Implikationen. Die FNAIT ist daher ein Krankheitsbild, das der interdisziplinären Beratung und Behandlung unter Beteilung von Frauenärzten, Pädiatern und Transfusionsmedizinern bedarf. Inzidenz, Pathogenese und Krankheitsbild der FNAIT werden ausführlich dargestellt und die diagnostischen und therapeutischen Möglichkeiten unter Berücksichtigung der aktuellen Studienlage diskutiert.

Abstract

In fetal / neonatal alloimmune thrombocytopenia (FNAIT), antibodies are formed by the mother against paternal antigens present on fetal platelets. These antibodies will cause thrombocytopenia of the fetus or newborn when transferred via the placenta into the circulation of the unborn. Intracranial bleeding is one severe complication in FNAIT. In immunized females, a subsequent pregnancy may need special diagnostic and prophylactic interventions. Thus, FNAIT requires interdisciplinary counselling and treatment involving specialists for obstetrics, paediatrics, and transfusion medicine. The incidence, the pathogenesis, and the clinical picture of FNAIT will be described in this review. The diagnostic and therapeutic options are discussed and recent studies in the field are appraised.

Schlüsselwörter

NAIT - neonatale Thrombozytopenie - FNAIT - Diagnostik - Therapie

Key words

NAIT - neonatal thrombocytopenia - FNAIT - diagnosis - therapy

Volltext

Referenzen

Literatur
1 Ultraschalldiagnostik in Pädiatrie und Kinderchirurgie. Hofmann V, Deeg K-H, Hoyer PF. Stuttgart: Thieme Verlag; 2005
2 Kamphuis MM, Paridaans N, Porcelijn L et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 2010; 117: 1335-1343
3 Knight M, Pierce M, Allen D et al. The incidence and outcomes of fetomaternal alloimmune thrombocytopenia: a UK national study using three data sources. Br J Haematol 2011; 152: 460-468
4 Tiller H, Killie MK, Skogen B et al. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. BJOG 2009; 116: 594-598
5 Gruel Y, Boizard B, Daffos F et al. Determination of platelet antigens and glycoproteins in the human fetus. Blood 1986; 68: 488-492
6 Kumpel BM, Sibley K, Jackson DJ et al. Ultrastructural localization of glycoprotein III a (GPIIIa, β3 integrin) on placental syncytiotrophoblast microvilli: implications for platelet alloimmunization during pregnancy. Transfusion 2008; 48: 2077-2086
7 Mueller-Eckhardt C, Kiefel V, Grubert A et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989; 1: 363-366
8 Reznikoff-Etievant MF, Muller JY, Julien F et al. An immune response gene linked to MHC in man. Tissue Antigens 1983; 22: 312-314
9 Mueller-Eckhardt C, Mueller-Eckhardt G, Willen-Ohff H et al. Immunogenicity of and immune response to the human platelet antigen Zwa is strongly associated with HLA-B8 and DR3. Tissue Antigens 1985; 26: 71-76
10 Kjeldsen-Kragh J, Killie MK, Tomter G et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007; 110: 833-839
11 Anani Sarab G, Moss M, Barker RN et al. Naturally processed peptides spanning the HPA-1a polymorphism are efficiently generated and displayed from platelet glycoprotein by HLA-DRB3*0101-positive antigen-presenting cells. Blood 2009; 114: 1954-1957
12 Williamson LM, Hackett G, Rennie J et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 1998; 92: 2280-2287
13 Simister NE, Story CM, Chen HL et al. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol 1996; 26: 1527-1531
14 Leach JL, Sedmak DD, Osborne JM et al. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol 1996; 157: 3317-3322
15 Chen P, Li C, Lang S et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood 2010; 116: 3660-3668
16 Bussel JB, Zabusky MR, Berkowitz RL et al. Fetal alloimmune thrombocytopenia. N Engl J Med 1997; 337: 22-26
17 Ghevaert C, Campbell K, Walton J et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 2007; 47: 901-910
18 Kroll H, Yates J, Santoso S. Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion 2005; 45: 353-358
19 Davoren A, Curtis B, Aster R et al. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004; 44: 1220-1225
20 Ohto H, Miura S, Ariga H et al. The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med 2004; 14: 399-408
21 Panzer S, Auerbach L, Cechova E et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol 1995; 90: 655-660
22 Kaplan C, Morel-Kopp MC, Kroll H et al. HPA-5b (Br(a)) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991; 78: 425-429
23 Ertel K, Al-Tawil M, Santoso S et al. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005; 45: 366-373
24 Bakchoul T, Kubiak S, Krautwurst A et al. Low-avidity anti-HPA-1a alloantibodies are capable of antigen-positive platelet destruction in the NOD / SCID mouse model of alloimmune thrombocytopenia. Transfusion 2011; 51: 2455-2461
25 Bussel J, Zacharoulis S, Kramer K et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005; 45: 176-183
26 Thude H, Schorner U, Helfricht C et al. Neonatal alloimmune thrombocytopenia caused by human leucocyte antigen-B27 antibody. Transfus Med 2006; 16: 143-149
27 Taaning E. HLA antibodies and fetomaternal alloimmune thrombocytopenia: myth or meaningful?. Transfus Med Rev 2000; 14: 275-280
28 Curtis BR, Fick A, Lochowicz AJ et al. Neonatal alloimmune thrombocytopenia associated with maternal-fetal incompatibility for blood group B. Transfusion 2008; 48: 358-364
29 Kroll H, Penke G, Santoso S. Functional heterogeneity of alloantibodies against the human platelet antigen (HPA)-1a. Thromb Haemost 2005; 94: 1224-1229
30 van Gils JM, Stutterheim J, van Duijn TJ et al. HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. Molecular Immunology 2009; 46: 406-415
31 Tiller H, Killie MK, Husebekk A et al. Platelet antibodies and fetal growth: maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys. Acta Obstet Gynecol Scand (Acta Obstetricia et Gynecologica Scandinavica) 2012; 91: 79-86
32 Althaus J, Weir E, Askin F et al. Chronic villitis in untreated neonatal alloimmune thrombocytopenia: an etiology for severe early intrauterine growth restriction and the effect of intravenous immunoglobulin therapy. Am J Obstet Gynecol 2005; 193: 1100-1104
33 Li C, Piran S, Chen P et al. The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011; 121: 4537-4547
34 Giovangrandi Y, Daffos F, Kaplan C et al. Very early intracranial haemorrhage in alloimmune fetal thrombocytopenia. Lancet 1990; 336: 310
35 Dale S, Coleman L. Neonatal alloimmune thrombocytopenia: antenatal and postnatal imaging findings in the pediatric brain. AJNR Am J Neuroradiol 2002; 23: 1457-1465
36 Bonacossa IA, Jocelyn LJ. Alloimmune thrombocytopenia of the newborn: neurodevelopmental sequelae. Am J Perinatol 1996; 13: 211-215
37 Birchall J, Murphy M, Kaplan C et al. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 2003; 122: 275-288
38 Dreyfus M, Kaplan C, Verdy E et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood 1997; 89: 4402-4406
39 Uhrynowska M, Maslanka K, Zupanska B. Neonatal thrombocytopenia: incidence, serological and clinical observations. Am J Perinatol 1997; 14: 415-418
40 Sola-Visner M, Saxonhouse MA, Brown RE. Neonatal thrombocytopenia: What we do and don’t know. Early Hum Dev 2008; 84: 499-506
41 Chakravorty S, Murray N, Roberts I. Neonatal thrombocytopenia. Early Hum Dev 2005; 81: 35-41
42 Holzhauer S, Zieger B. Diagnosis and management of neonatal thrombocytopenia. Semin Fetal Neonatal Med 2011; 16: 305-310
43 Kiefel V, Santoso S, Weisheit M et al. Monoclonal antibody – specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-1726
44 Campbell K, Rishi K, Howkins G et al. A modified rapid monoclonal antibody-specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies: a multicentre evaluation. Vox Sang 2007; 070926073051002
45 Nguyen XD, Goebel M, Schober M et al. The detection of platelet antibodies by simultaneous analysis of specific platelet antibodies and the monoclonal antibody-specific immobilization of platelet antigens: an interlaboratory comparison. Transfusion 2010; 50: 1429-1434
46 Bakchoul T, Meyer O, Agaylan A et al. Rapid detection of HPA-1 alloantibodies by platelet antigens immobilized onto microbeads. Transfusion 2007; 47: 1363-1368
47 Killie M, Husebekk A, Kjeldsen-Kragh J et al. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 2008; 93: 870-877
48 Socher I, Andrei-Selmer C, Bein G et al. Low-avidity HPA-1a alloantibodies in severe neonatal alloimmune thrombocytopenia are detectable with surface plasmon resonance technology. Transfusion 2009; 49: 943-952
49 Socher I, Zwingel C, Santoso S et al. Heterogeneity of HPA-3 alloantibodies: consequences for the diagnosis of alloimmune thrombocytopenic syndromes. Transfusion 2008; 48: 463-472
50 Carl B, Kroll H, Bux J et al. B-lymphoblastoid cell lines as a source of reference DNA for human platelet and neutrophil antigen genotyping. Transfusion 2000; 40: 62-68
51 Ficko T, Galvani V, Rupreht R et al. Real-time PCR genotyping of human platelet alloantigens HPA-1, HPA-2, HPA-3 and HPA-5 is superior to the standard PCR-SSP method. Transfus Med 2004; 14: 425-432
52 Scheffer PG, Ait SoussanA, Verhagen O et al. Noninvasive fetal genotyping of human platelet antigen-1a. BJOG 2011; 118: 1392-1395
53 Bertrand G, Martageix C, Jallu V et al. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost 2006; 4: 628-637
54 Jaegtvik S, Husebekk A, Aune B et al. Neonatal alloimmune thrombocytopenia due to anti-HPA 1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. BJOG 2000; 107: 691-694
55 Bessos H, Killie M, Seghatchian J et al. The relationship of anti-HPA-1a amount to severity of neonatal alloimmune thrombocytopenia – Where does it stand?. Transfus Apher Sci 2009; 40: 75-78
56 Bertrand G, Drame M, Martageix C et al. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood 2011; 117: 3209-3213
57 Bussel JB. Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost 2009; 7: 253-257
58 Baer VL, Lambert DK, Henry E et al. Severe Thrombocytopenia in the NICU. Pediatrics 2009; 124: 1095-1100
59 Chakravorty S, Roberts I. How I manage neonatal thrombocytopenia. Br J Haematol 2012; 156: 155-162
60 Allen DL, Samol J, Benjamin S et al. Survey of the use and clinical effectiveness of HPA-1a / 5b-negative platelet concentrates in proven or suspected platelet alloimmunization. Transfus Med 2004; 14: 409-417
61 Kiefel V, Bassler D, Kroll H et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006; 107: 3761-3763
62 Allen D, Verjee S, Rees S et al. Platelet transfusion in neonatal alloimmune thrombocytopenia. Blood 2007; 109: 388-389
63 Bakchoul T, Sachs UJ, Wittekindt B et al. Treatment of fetomaternal neonatal alloimmune thrombocytopenia with random platelets. Pediatr Blood Cancer 2008; 50: 1293-1294
64 Roberts I, Murray NA. Neonatal thrombocytopenia. Semin Fetal Neonatal Med 2008; 13: 256-264
65 Sidiropoulos D, Straume B. The treatment of neonatal isoimmune thrombocytopenia with intravenous immunoglobin (IgG i. v.). Blut 1984; 48: 383-386
66 Massey GV, McWilliams NB, Mueller DG et al. Intravenous immunoglobulin in treatment of neonatal isoimmune thrombocytopenia. J Pediatr 1987; 111: 133-135
67 Bussel JB, Berkowitz RL, Hung C et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol 2010; 203: 135.e1
68 Kamphuis M, Oepkes D. Fetal and neonatal alloimmune thrombocytopenia: prenatal interventions. Prenat Diagn 2011; 31: 712-719
69 Rayment R, Brunskill SJ, Soothill PW et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev; 2011 CD004226
70 Daffos F, Forestier F, Muller JY et al. Prenatal treatment of alloimmune thrombocytopenia. Lancet 1984; 2: 632
71 Paidas MJ, Berkowitz RL, Lynch L et al. Alloimmune thrombocytopenia: Fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995; 172: 475-479
72 Bussel JB, Berkowitz RL, McFarland JG et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988; 319: 1374-1378
73 Lynch L, Bussel JB, McFarland JG et al. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol 1992; 80: 67-71
74 Bussel JB, Berkowitz RL, Lynch L et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 1996; 174: 1414-1423
75 Dawkins B, Minchinton RM. Fetomaternal alloimmune thrombocytopenia treated with intragam. Med J Aust 1999; 170: 451-452
76 Mackenzie F, Brennand J, Peterkin M et al. Management of fetal alloimmune thrombocytopenia-a less invasive option?. J Obstet Gynaecol 1999; 19: 119-121
77 Sainio S, Teramo K, Kekomaki R. Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia. Transfus Med 1999; 9: 321-330
78 Berkowitz R, Kolb E, McFarland J et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 2006; 107: 91-96
79 Yinon Y, Spira M, Solomon O et al. Antenatal noninvasive treatment of patients at risk for alloimmune thrombocytopenia without a history of intracranial hemorrhage. Am J Obstet Gynecol 2006; 195: 1153-1157
80 Berkowitz R, Lesser M, McFarland J et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol 2007; 110: 249-255
81 van den Akker ES, Oepkes D, Lopriore E et al. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG 2007; 114: 469-473
82 Giers G, Wenzel F, Stockschlader M et al. Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion. Haematologica 2010; 95: 1921-1926
83 Palfi M, Selbing A. Placental transport of maternal immunoglobulin G. Am J Reprod Immunol 1998; 39: 24-26
84 Fogliarini C, Chaumoitre K, Chapon F et al. Assessment of cortical maturation with prenatal MRI. Part I: normal cortical maturation. Eur Radiol 2005; 15: 1671-1685
85 Fogliarini C, Chaumoitre K, Chapon F et al. Assessment of cortical maturation with prenatal MRI: part II: abnormalities of cortical maturation. Eur Radiol 2005; 15: 1781-1789
86 Levine D. Magnetic resonance imaging in prenatal diagnosis. Curr Opin Pediatr 2001; 13: 572-578
87 Reddy UM, Filly RA, Copel JA. Prenatal Imaging. Obstet Gynecol 2008; 112: 145-157
88 van den Akker ES, Oepkes D, Brand A et al. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia?. BJOG 2006; 113: 781-783
89 Bakchoul T, Boylan B, Sachs UJH et al. Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab′) 2 in an in vivo mouse model of alloimmune thrombocytopenia. Transfusion 2009; 49: 265-270
90 Tiller H, Killie MK, Chen P et al. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion 2012; In press